ABOUT US

​

​In over 50 years there was little development in the treatment of chronic kidney disease. At inRegen we are pioneers in the field of Chronic kidney treatment.

HIGHLIGHTS

FDA awarded Fast Track Designation

ReACT Potential health care cost off-set equals approximately $250K/patient/year

Long-term durability in clinical trials supports of approximately 5 year delay in renal failure over standard of care. ​

Partnership with the National Kidney Foundation (NKF) and the American Association of Kidney Patients (AAKP)

DEVELOPED TECHNOLOGY​

inRegen’s technology has the potential to create new human tissues and kidneys (neo-tissues and neo-organs) by using the patient’s own (autologous) kidney cells. By contrast, organ transplantation from other donors (allogenic transplants) can be associated with organ rejection and failure. Further, the patient lives with the adverse effects of immunosuppression.

​

​inRegen's patented technology uses multiple breakthroughs in manufacturing, automation, supply chain, and delivery technologies.  While it has long been held that the body contains cells with regenerative power, inRegen's technology is able to identify these cells and harness them to create a specific repair, restoration and function improvements of chronically diseased kidneys  on a commercial scale.​

inRegen’s kidney restoration process begins with a patient’s biopsy. inRegen is able to identify the patient’s own healthy progenitor cells, and formulate them into a personalized product that can be injected into the damaged kidney for repair,  regeneration and restoration of function. When the personalized product (REACT ™) is injected  into the patient’s diseased kidney, it is programmed to integrate into the damaged tissues and attract other healing cells, controlling inflammation, fibrosis and angiogenesis to form new functioning tissues and ultimately, a healthy kidney.

​

​